Platelet-activating factor is a key mediator of pulmonary vasoconstriction and bronchoconstriction after antigen challenge in the perfused sensitized rabbit lung.
Exposure of sensitized perfused rabbit lungs to human O-N type erythrocytes leads to pulmonary vasoconstriction and bronchoconstriction. To investigate whether platelet-activating factor (PAF) is a mediator of pulmonary vasoconstrictive and bronchoconstrictive responses after antigen challenge, we administered antigenic erythrocytes after the administration of PAF antagonist (.1 mg/kg; CV6209). Pulmonary arterial and airway pressures significantly increased after antigen challenge in the sensitized rabbit lungs, but not in the nonsensitized rabbit lungs. CV6209 significantly inhibited these pulmonary vasoconstrictive and bronchoconstrictive responses after antigen challenge. We concluded that PAF, at least in part, plays an important role in pulmonary vasoconstriction and bronchoconstriction after antigen challenge in rabbits.
Shouji
K
K
Department of Anesthesiology, Akita Kumiai General Hospital, Japan.
Enzan
K
K
Mitsuhata
H
H
Yoshioka
N
N
D000818:Animals; D000941:Antigens / Q000276:immunology*; D016084:Bronchoconstriction / Q000502:physiology*; D046508:Culture Techniques; D004912:Erythrocytes / Q000276:immunology; D006801:Humans; D008168:Lung / Q000276:immunology*; D010477:Perfusion; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D011652:Pulmonary Circulation; D011726:Pyridinium Compounds / Q000494:pharmacology*; D011817:Rabbits; D014661:Vasoconstriction / Q000502:physiology*
D000941:Antigens; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; C053321:CV 6209